Inflammatory bowel disease: new therapies from antisense oligonucleotides
- 4 July 2018
- journal article
- review article
- Published by Taylor & Francis in Annals of Medicine
- Vol. 50 (5) , 361-370
Abstract
Inflammatory bowel diseases (IBD) are chronic inflammatory conditions of the gastrointestinal tract encompassing two main clinical entities: Crohn’s disease (CD) and ulcerative colitis (UC). These disorders are characterized by various grades of tissue damage and development of local complications and extra-intestinal manifestations. The cause of IBD remains unknown but accumulating evidence indicates that both CD and UC arise in genetically predisposed individuals as a result of the action of multiple environmental factors, which ultimately trigger excessive and poorly controlled immune response against antigens of the luminal flora. Despite this realization, a full understanding of IBD pathogenesis is still out of reach and, consequently, treatment is far from optimal. However, in recent years, several pathways of intestinal damage have been delineated and the improved knowledge has contributed to the development of new therapies. Various approaches have been used to either inhibit the expression and/or function of inflammatory molecules or enhance counter-regulatory mechanisms. This review summarizes the available pre-clinical and clinical data for antisense oligonucleotides and oligonucleotide-based therapy to provide a comprehensive understanding of the rationale and mechanism of action of these compounds in IBD.Keywords
This publication has 100 references indexed in Scilit:
- Molecular function of macrophage migration inhibitory factor and a novel therapy for inflammatory bowel diseaseAnnals of the New York Academy of Sciences, 2012
- A New Therapeutic Approach Using a Schizophyllan-based Drug Delivery System for Inflammatory Bowel DiseaseMolecular Therapy, 2012
- Phase I Clinical Trial of Smad7 Knockdown Using Antisense Oligonucleotide in Patients With Active Crohn's DiseaseMolecular Therapy, 2012
- Transcript levels of Toll-Like receptors 5, 8 and 9 correlate with inflammatory activity in Ulcerative ColitisBMC Gastroenterology, 2011
- Toll-like Receptors and Their Crosstalk with Other Innate Receptors in Infection and ImmunityImmunity, 2011
- Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytesNucleic Acids Research, 2011
- Inflammatory Bowel DiseaseNew England Journal of Medicine, 2009
- G3139, an Anti-Bcl-2 Antisense Oligomer That Binds Heparin-Binding Growth Factors and Collagen I, AltersIn vitroEndothelial Cell Growth and Tubular MorphogenesisClinical Cancer Research, 2009
- Unravelling the pathogenesis of inflammatory bowel diseaseNature, 2007
- Transforming growth factor-β in T-cell biologyNature Reviews Immunology, 2002